The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease

Clinics in Liver Disease

Volumn 22, Issue 1, 2018, Pages 121-132

  Puri, Puneet ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

16S pyrosequencing; Cirrhosis; Innate immune system; Intestinal permeability; Microbiome; Microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 5; LIPOPOLYSACCHARIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; RNA 16S; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ALCOHOL BLOOD LEVEL; AMINO ACID METABOLISM; AMPLICON; BACTEROIDETES; BODY MASS; CARBOHYDRATE METABOLISM; DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE COURSE; FIRMICUTES; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; LIPID METABOLISM; LIVER CANCER; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; METABOLIC SYNDROME X; MICROBIOME; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEOBACTERIA; REVIEW; SIGNAL TRANSDUCTION; STEATOSIS; BIOLOGY; HEPATITIS; IMMUNOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY;

COMPUTATIONAL BIOLOGY; GASTROINTESTINAL MICROBIOME; HEPATITIS; HUMANS; IMMUNITY, INNATE; INTESTINES; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; TOLL-LIKE RECEPTORS;

EID: 85034607986     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2017.08.009     Document Type: Review

References (48)

1. Lynch, S.V., Pedersen, O., The human intestinal microbiome in health and disease. N Engl J Med 375 (2016), 2369–2379.
2. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
3. Eid, J., Fehr, A., Gray, J., et al. Real-time DNA sequencing from single polymerase molecules. Science 323 (2009), 133–138.
4. Berglund, E.C., Kiialainen, A., Syvanen, A.C., Next-generation sequencing technologies and applications for human genetic history and forensics. Investig Genet, 2, 2011, 23.
5. Wang, Q., Garrity, G.M., Tiedje, J.M., et al. Naïve bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73 (2007), 5261–5267.
6. Naqvi, A., Rangwala, H., Spear, G., et al. Analysis of multitag pyrosequence data from human cervical lavage samples. Chem Biodivers 7 (2010), 1076–1085.
7. Caporaso, J.G., Kuczynski, J., Stombaugh, J., et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7 (2010), 335–336.
8. Schloss, P.D., Westcott, S.L., Ryabin, T., et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75 (2009), 7537–7541.
9. Langille, M.G.I., Zaneveld, J., Caporaso, J.G., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotech 31 (2013), 814–821.
10. Kanehisa, M., Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28 (2000), 27–30.
11. Segata, N., Izard, J., Walron, L., et al. Metagenomic biomarker discovery and explanation. Genome Biol, 12, 2011, R60.
12. White, J.R., Nagarajan, N., Pop, M., Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol, 5, 2009, e1000352.
13. Sunagawa, S., Mende, D.R., Zeller, G., et al. Metagenomic species profiling using universal phylogenetic marker genes. Nat Methods 10 (2013), 1196–1199.
14. Jones, M.B., Highlander, S.K., Anderson, E.L., et al. Library preparation methodology can influence genomic and functional predictions in human microbiome research. Proc Natl Acad Sci USA 112 (2015), 14024–14029.
15. Naqvi, A., Rangwale, H., Keshavarzian, A., et al. Network-based modeling of the human gut microbiome. Chem Biodiversity 7 (2010), 1040–1050.
16. Shannon, P., Markiel, A., Ozier, O., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13 (2003), 2498–2504.
17. Sanyal, A.J., Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005), 46–53.
18. Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001), 1183–1192.
19. Turnbaugh, P.J., Backhed, F., Fulton, L., et al. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3 (2008), 213–223.
20. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
21. Ridlon, J.M., Ikegawa, S., Alves, J.M., et al. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res 54 (2013), 2437–2449.
22. Thomas, C., Gioiello, A., Noriega, L., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10 (2009), 167–177.
23. Kumar, D.P., Asgharpour, A., Mirshahi, F., et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis. J Biol Chem 291 (2016), 6626–6640.
24. Glass, C.K., Olefsky, J.M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15 (2012), 635–645.
25. Fu, S., Watkins, S.M., Hotamisligil, G.S., The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab 15 (2012), 623–634.
26. Boga, S., Alkim, H., Koksal, A.R., et al. Increased plasma levels of asymmetric dimethylarginine in nonalcoholic fatty liver disease: relation with insulin resistance, inflammation, and liver histology. J Investig Med 63 (2015), 871–877.
27. Csak, T., Pillai, A., Ganz, M., et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int 34 (2014), 1402–1413.
28. Dinarello, C.A., Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27 (2009), 519–550.
29. Ratsimandresy, R.A., Dorfleutner, A., Stehlik, C., An update on PYRIN domain-containing pattern recognition receptors: from immunity to pathology. Front Immunol, 4, 2013, 440.
30. Ganz, M., Csak, T., Nath, B., et al. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol 17 (2011), 4772–4778.
31. Seki, E., De Minicis, S., Osterreicher, C.H., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13 (2007), 1324–1332.
32. Marra, F., Romanelli, R.G., Giannini, C., et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29 (1999), 140–148.
33. Friedman, S., Sanyal, A., Goodman, Z., et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials 47 (2016), 356–365.
34. Fabregat, I., Moreno-Caceres, J., Sanchez, A., et al. TGF-beta signalling and liver disease. FEBS J 283 (2016), 2219–2232.
35. Yan, X., Lin, Z., Chen, F., et al. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J Biol Chem 284 (2009), 30097–30104.
36. Ley, R.E., Turnbaugh, P.J., Klein, S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006), 1022–1023.
37. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
38. Le Chatelier, E., Nielsen, T., Qin, J., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500 (2013), 541–546.
39. Arumugam, M., Raes, J., Pelletier, E., et al. Enterotypes of the human gut microbiome. Nature 473 (2011), 174–180.
40. Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486 (2012), 207–214.
41. Finucane, M.M., Sharpton, T.J., Laurent, T.J., et al. A taxonomic signature of obesity in the microbiome? getting to the guts of the matter. PLoS One, 9, 2014, e84689.
42. Spencer, M.D., Hamp, T.J., Reid, R.W., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140 (2011), 976–986.
43. Zhu, L., Baker, S.S., Gill, C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57 (2013), 601–609.
44. Yuan, J., Baker, S.S., Liu, W., et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol 29 (2014), 1292–1298.
45. Mouzaki, M., Comelli, E.M., Arendt, B.M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58 (2013), 120–127.
46. Raman, M., Ahmed, I., Gillevet, P.M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11 (2013), 868–875.e1–3.
47. Boursier, J., Mueller, O., Barret, M., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63 (2016), 764–775.
48. Loomba, R., Seguritan, V., Li, W., et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25 (2017), 1054–1062.e5.